GeneBio Systems

FGF23 ELISA kit (Human)

Name: FGF23 ELISA kit (Human)
Brand: GeneBio Systems
SKU: SEA746Hu
Price: 769.00 GBP
Availability: InStock

SKU:SEA746Hu

£769.00 GBP

Sale Sold out

Shipping calculated at checkout.

Quantity

Size: 96Tests

# of Times Cited in literature: 25

Prepare Time: 1-3 days(please inquire for mutiple units)

Target Name: FGF23

Target Full Name: Fibroblast Growth Factor 23

Alternative Names: ADHR; HYPF; HPDR2; PHPTC; Phosphatonin; Tumor-derived hypophosphatemia-inducing factor

Target Species: Human

Uniprot: Q9GZV9

Gene ID: 8074

Featured Series: SE kit

Featured Series Function: Detects protein (regular version)

Specificity: Reactive with Human FGF23 / Fibroblast Growth Factor 23

Method: Colormetric

Detection principle: Double-antibody Sandwich

Detection range: 15.6-1,000pg/mL

Sensitivity: 6.2pg/mL

Assay Time: 3h

Sample Size: 100uL

Recommended/Predicted Sample Types: Serum, Plasma, Tissue Homogenates, Cell Lysates, Cell Culture Supernates and other Biological Fluids

Assay Precision: Intra-Assay: CV<10%, Inter-Assay: CV<12%

Reproducibility test menthod: Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Fibroblast Growth Factor 23 (FGF23) were tested 20 times on one plate, respectively. Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Fibroblast Growth Factor 23 (FGF23) were tested on 3 different plates, 8 replicates in each plate. CV(%) = SD/meanX100

Storage: 4°C for 1 month/ -20°C for long-term(One year within shelf life)

Shelf-life: 12 months

Specificity: This assay has high sensitivity and excellent specificity for detection of Fibroblast Growth Factor 23 (FGF23). No significant cross-reactivity or interference between Fibroblast Growth Factor 23 (FGF23) and analogues was observed.

Stability: The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition. To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Assay procedure summary: 1. Prepare all reagents, samples and standards; 2. Add 100µL standard or sample to each well. Incubate 1 hours at 37°C; 3. Aspirate and add 100µL prepared Detection Reagent A. Incubate 1 hour at 37°C; 4. Aspirate and wash 3 times; 5. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C; 6. Aspirate and wash 5 times; 7. Add 90µL Substrate Solution. Incubate 10-20 minutes at 37°C; 8. Add 50µL Stop Solution. Read at 450nm immediately.

Test principle: The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Fibroblast Growth Factor 23 (FGF23). Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody specific to Fibroblast Growth Factor 23 (FGF23). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Fibroblast Growth Factor 23 (FGF23), biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Fibroblast Growth Factor 23 (FGF23) in the samples is then determined by comparing the O.D. of the samples to the standard curve.

Research Area: Cytokine;Tumor immunity;Infection immunity;Genetic science;

References Citing This Product: Prognostic impact of renal function in precapillary pulmonary hypertension

FGF-23 associated with the progression of coronary artery calcification in hemodialysis patients

Lower Fibroblast Growth Factor 23 Levels in Young Adults With Crohn Disease as a Possible Secondary Compensatory Effect on the Disturbance of Bone and Mineral Metabolism

Prognostic impact of renal function in precapillary pulmonary hypertension.

Fibroblast growth factor is associated to left ventricular mass index, anemia and low values of transferrin saturation El factor de crecimiento fibroblástico está asociado con el índice de masa ventricular izquierda, anemia y niveles bajos de saturación de la transferrina

An Attempt to Evaluate Selected Aspects of “Bone–Fat Axis” Function in Healthy Individuals and Patients With Pancreatic Cancer

Les biomarqueurs des calcifications vasculaires: quelles limites analytiques pour leur transfert de la recherche bioclinique à la pratique?

High-dose fast infusion of parenteral iron isomaltoside is efficacious in inflammatory bowel disease patients with iron-deficiency anaemia without profound changes in phosphate or fibroblast growth factor 23

Evaluation of concentration fibroblast growth factor FGF-23 in hemodialysed patients and after kidney transplantation

Associations between serum fibroblast growth factor 23 level and intradialytic hypotension in hemodialysis patients

ADAM17, a New Player in the Pathogenesis of Chronic Kidney Disease-Mineral and Bone Disorder.